Terms: = Leukemia AND TAL1, TCL5, 6886, ENSG00000162367, SCL, P17542, tal-1 AND Treatment
74 results:
1. Suppression of super-enhancer-driven tal1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
[TBL] [Abstract] [Full Text] [Related]
3. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic leukemia.
O'Connor D; Demeulemeester J; Conde L; Kirkwood A; Fung K; Papaleonidopoulou F; Bloye G; Farah N; Rahman S; Hancock J; Bateman C; Inglott S; Mee J; Herrero J; Van Loo P; Moorman AV; Vora A; Mansour MR
J Clin Oncol; 2023 Jul; 41(19):3545-3556. PubMed ID: 37098241
[TBL] [Abstract] [Full Text] [Related]
4. Harnessing the MYB-dependent tal1 5'super-enhancer for targeted therapy in T-ALL.
Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
[TBL] [Abstract] [Full Text] [Related]
5. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
Aiba M; Shigematsu A; Suzuki T; Miyagishima T
Ann Hematol; 2023 Mar; 102(3):541-546. PubMed ID: 36646889
[TBL] [Abstract] [Full Text] [Related]
6. [Characteristics and prognostic effects of NOTCH1/FBXW7 gene mutations in T-cell acute lymphoblastic leukemia patients].
Wu CY; Li YL; Dong XY; Yang SW; Shang BJ; Zhang L; Cheng W; Zhang L; Zhu ZM
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(25):1910-1917. PubMed ID: 35768390
[No Abstract] [Full Text] [Related]
7. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
[TBL] [Abstract] [Full Text] [Related]
8. Hirsutine, a novel megakaryopoiesis inducer, promotes thrombopoiesis via MEK/ERK/FOG1/tal1 signaling.
Kang Y; Lin J; Wang L; Shen X; Li J; Wu A; Yue L; Wei L; Ye Y; Yang J; Wu J
Phytomedicine; 2022 Jul; 102():154150. PubMed ID: 35569185
[TBL] [Abstract] [Full Text] [Related]
9. Functional Evaluation of KEL as an Oncogenic Gene in the Progression of Acute Erythroleukemia.
Liu W; Wu Z; Yu Y; Qiao C; Zhu H; Hong M; Zhu Y; Qian S; Chen S; Wu D; Li J; Jin H
Oxid Med Cell Longev; 2022; 2022():5885342. PubMed ID: 35140839
[TBL] [Abstract] [Full Text] [Related]
10. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
[TBL] [Abstract] [Full Text] [Related]
11. Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup.
Touzart A; Mayakonda A; Smith C; Hey J; Toth R; Cieslak A; Andrieu GP; Tran Quang C; Latiri M; Ghysdael J; Spicuglia S; Dombret H; Ifrah N; Macintyre E; Lutsik P; Boissel N; Plass C; Asnafi V
Sci Transl Med; 2021 May; 13(595):. PubMed ID: 34039737
[TBL] [Abstract] [Full Text] [Related]
12. Dengue virus infection impedes megakaryopoiesis in MEG-01 cells where the virus envelope protein interacts with the transcription factor tal-1.
Banerjee A; Tripathi A; Duggal S; Banerjee A; Vrati S
Sci Rep; 2020 Nov; 10(1):19587. PubMed ID: 33177556
[TBL] [Abstract] [Full Text] [Related]
13. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes tal1 in T-Cell Acute Lymphoblastic leukemia.
Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
[TBL] [Abstract] [Full Text] [Related]
14. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
15. Eradication of Central Nervous System leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.
Saito S; Kikuchi J; Koyama D; Sato S; Koyama H; Osada N; Kuroda Y; Akahane K; Inukai T; Umehara T; Furukawa Y
Clin Cancer Res; 2019 Mar; 25(5):1601-1611. PubMed ID: 30518632
[TBL] [Abstract] [Full Text] [Related]
16. [Study on Immunophenotypes and Gene of Acute Lymphoblastic leukemia].
Zhao XF; Wang HY; Zhao X; Cheng HC; Li W; Liu SW; Qiu L; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):947-952. PubMed ID: 30111389
[TBL] [Abstract] [Full Text] [Related]
17. [Genetic basis of pediatric T-cell acute lymphoblastic leukemia and its clinical impact].
Takita J
Rinsho Ketsueki; 2018; 59(7):953-959. PubMed ID: 30078808
[TBL] [Abstract] [Full Text] [Related]
18. MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB.
Cordas Dos Santos DM; Eilers J; Sosa Vizcaino A; Orlova E; Zimmermann M; Stanulla M; Schrappe M; Börner K; Grimm D; Muckenthaler MU; Kulozik AE; Kunz JB
BMC Cancer; 2018 Jun; 18(1):663. PubMed ID: 29914415
[TBL] [Abstract] [Full Text] [Related]
19. The effect of vitamin D and zoledronic acid in bone marrow adiposity in kidney transplant patients: A post hoc analysis.
Hernandez MJ; Dos Reis LM; Marques ID; Araujo MJ; Truyts CAM; Oliveira IB; Barreto FC; David-Neto E; Custodio MR; Moyses RM; Bellorin-Font E; Jorgetti V
PLoS One; 2018; 13(5):e0197994. PubMed ID: 29799857
[TBL] [Abstract] [Full Text] [Related]
20. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
[TBL] [Abstract] [Full Text] [Related]
[Next]
